New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
11:48 EDTMYGNMyriad Genetics test predicts response to platinum therapy in triple-negative BC
Myriad Genetics announced that a presentation entitled "Homologous recombination deficiency, HRD, score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer, BC," was presented on Friday, December 7, at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. The study demonstrates that Myriad's HRD test strongly predicts which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer. Triple-negative breast cancer describes breast tumors that lack estrogen receptor, progesterone receptor and HER2. This type of breast cancer tends to be more aggressive than other subtypes of breast cancer and has not been amenable to targeted therapies. The platinum class of drugs kill tumors by causing DNA damage inside the tumor and may be particularly effective against tumors that have lost their ability to repair DNA.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2015
14:20 EDTMYGNWilliam Blair diagnostic services analyst holds analyst/industry conference call
Analysts, along with Dr. Todd Cohen, provide an industry update on an Analyst/Industry conference call to be held on April 16 at 3 pm.
April 8, 2015
08:45 EDTMYGNLife Sciences group well positioned heading into Q1 earnings, says Cowen
Cowen said the Life Sciences sector looks well positioned heading into Q1 earnings despite the group outperforming the broader market recently. The firm believes headwinds have intensified and multiples have stretched, but they see the downside risk as limited with upside risk dependent on improving end-market commentary, new products and milestones, and new details on capital deployment. Stocks in the space include Affymetrix (AFFX), Fluidigm (FLDM), GenMark (GNMK), Myriad Genetics (MYGN) and Quidel (QDEL).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use